Arrowhead Pharmaceuticals Inc. (ARWR) Reports Q1 Loss of $0.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $59.90 +0.55%
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.20), versus ($0.03) reported last year. Revenue for the quarter came in at $21.3 million, versus $29.46 million reported last year.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c
- Moody’s lifts Nokia to Baa3 investment grade on AI and cloud momentum
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
